Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Stem Cell Therapy Alofisel Wins European Approval: Takeda
The European Commission (EC) has approved Takeda Pharmaceutical/TiGenix’s Alofisel (darvadstrocel), the first allogeneic stem cell therapy in Europe, for the treatment of complex perianal fistulas associated with Crohn’s disease (CD), the companies said. Alofisel, previously known as Cx601, was approved…
To read the full story
Related Article
- Takeda Completes TiGenix Acquisition
August 1, 2018
- Takeda Snaps Up Cell Therapy Partner TiGenix in GI, Partners with Denali in CNS
January 9, 2018
- Takeda/TiGenix Cell Therapy for Crohn’s Disease Complication Gets European Panel Nod
December 19, 2017
BUSINESS
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Sumitomo to Launch Post-Marketing Study for iPSC Therapy by Year-End
March 9, 2026
- Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
- Nitrosamine Detected in Nichi-Iko’s Tryptanol, No Need to Halt Prescriptions
March 9, 2026
- Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…